Benzinga · Aug 3, 2026
HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $80
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex (NASDAQ:ENLV) with a Buy and raises the price target from $20 to $80.
EN
NASDAQ · ENLV
Enlivex Therapeutics Ltd.
Healthcare · Biotechnology
$1.04
Down-$0.06 (-5.70%)
Updated Sep 10, 2026, 9:38 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.6M
- P/E ratio
- -1.84
- Dividend yield
- 0.00%
- 52-week range
- $0.52 – $8.12
- Volume
- 287.78K
- Avg. volume
- 3.73M
Price performance
ENLV price history
1M range · 20 trading sessions · Daily adjusted prices
ENLV closed at $1.04 after 20 trading sessions, down 43.48% for the selected period.
- Last close
- $1.04
- Period change
- -43.48%
- Period low
- $1.04
- Period high
- $1.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.12 | $1.2171 | $1.02 | $1.04 | 287.78K |
| Sep 8, 2026 | $1.10 | $1.19 | $1.06 | $1.11 | 190.5K |
| Sep 4, 2026 | $1.15 | $1.16 | $1.02 | $1.10 | 252.14K |
| Sep 3, 2026 | $1.25 | $1.275 | $1.13 | $1.16 | 293.98K |
| Sep 2, 2026 | $1.29 | $1.30 | $1.21 | $1.25 | 227.5K |
| Sep 1, 2026 | $1.27 | $1.31 | $1.20 | $1.28 | 343.34K |
| Aug 31, 2026 | $1.33 | $1.34 | $1.15 | $1.28 | 403.71K |
| Aug 28, 2026 | $1.50 | $1.575 | $1.345 | $1.35 | 531.3K |
| Aug 27, 2026 | $1.51 | $1.66 | $1.47 | $1.475 | 519.25K |
| Aug 26, 2026 | $1.52 | $1.62 | $1.46 | $1.515 | 149.87K |
| Aug 25, 2026 | $1.49 | $1.57 | $1.46 | $1.52 | 162.43K |
| Aug 24, 2026 | $1.48 | $1.56 | $1.44 | $1.51 | 148.74K |
| Aug 21, 2026 | $1.49 | $1.52 | $1.39 | $1.47 | 157.53K |
| Aug 20, 2026 | $1.68 | $1.70 | $1.455 | $1.50 | 270.88K |
| Aug 19, 2026 | $1.50 | $1.81 | $1.47 | $1.73 | 295.1K |
| Aug 18, 2026 | $1.57 | $1.58 | $1.4801 | $1.52 | 148.02K |
| Aug 17, 2026 | $1.59 | $1.6199 | $1.54 | $1.58 | 174.79K |
| Aug 14, 2026 | $1.71 | $1.71 | $1.53 | $1.58 | 342.4K |
| Aug 13, 2026 | $1.94 | $1.98 | $1.68 | $1.69 | 451.64K |
| Aug 12, 2026 | $2.00 | $2.18 | $1.72 | $1.84 | 644.01K |
Latest ENLV news
The latest Smart Investors Daily articles mentioning ENLV.
Stock researchCompany · Overview
ENLV research
Overview
Company profile and research snapshot.
Company profile
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 12, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | D. Boral Capital | Hold | — |
| Oct 29, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
Enlivex Announces Trading Volume On Rain Protocol Reaches $860M
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. Trading
Benzinga · Jul 28, 2026
Enlivex Announces $400M Private Placement With A Single Institutional Investor Priced At $5.00 Per Share
Price of $5.00 per share for subscription amounts funded in U.S. dollars, USDT or USD Coin and $6.00 per share for subscription amounts funded in RAIN tokens, the $5.00 price representing a premium of 17.4% and the
Benzinga · Jun 22, 2026
Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
